The cobas® EGFR Mutation Test v2 from Roche was the first liquid biopsy test approved by the USFDA in June 2016 for the detection of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations of NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.